SCYNEXIS (DB:135A) - Aandelenkoers, Nieuws & Analyse

135A Overzicht aandelen

SCYNEXIS, Inc., een biotechnologiebedrijf, ontwikkelt medicijnen om moeilijk te behandelen en geneesmiddelresistente infecties in de Verenigde Staten te overwinnen en te voorkomen. Meer informatie

135A fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 97.3% onder onze schatting van de reële waarde

De winst zal naar verwachting met 48.7% per jaar groeien

Analisten zijn het erover eens dat de aandelenkoers met 429.1% zal stijgen

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( €47M )

Volatiele aandelenkoers in de afgelopen 3 maanden

SCYNEXIS, Inc. Concurrenten

MPH Health Care

DB:93M1

€102.8m

Redx Pharma

DB:0RX

€65.0m

Cantourage Group

XTRA:HIGH

€57.9m

Pierrel

DB:2FJ0

€92.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor SCYNEXIS
Historische aandelenkoersen
Huidige aandelenkoers	US$1.16
52 Week Hoogtepunt	US$2.50
52 Week Laag	US$1.09
Bèta	1.5
11 maand verandering	-11.64%
3 maanden verandering	-10.97%
1 Jaar Verandering	-21.45%
33 jaar verandering	-82.03%
5 jaar verandering	-87.78%
Verandering sinds IPO	-98.13%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	135A	DE Pharmaceuticals	DE Markt
7D	7.0%	-0.3%	0.8%
1Y	-21.4%	-18.3%	8.6%

Rendement versus industrie: 135A presteerde slechter dan de German Pharmaceuticals -sector, die het afgelopen jaar een rendement van -18.3 % opleverde.

Rendement versus markt: 135A presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 8.6 % opleverde.

Prijsvolatiliteit

Is 135A's price volatile compared to industry and market?
135A volatility
135A Average Weekly Movement	8.0%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van 135A is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van 135A is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1999	29	David Angulo	www.scynexis.com

SCYNEXIS, Inc., een biotechnologiebedrijf, ontwikkelt geneesmiddelen om moeilijk te behandelen en geneesmiddelenresistente infecties in de Verenigde Staten te overwinnen en te voorkomen. Het biedt BREXAFEMME aan voor de behandeling van patiënten met vulvovaginale candidiasis (VVC) en terugkerende VVC. De belangrijkste productkandidaat van het bedrijf is Ibrexafungerp, een intraveneus geneesmiddel voor de behandeling van invasieve candidiasis en/of candidemie, refractaire invasieve schimmelinfecties, invasieve aspergillose, VVC en terugkerende VVC.

SCYNEXIS, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van SCYNEXIS zich tot de beurswaarde?
135A fundamentele statistieken
Marktkapitalisatie	€44.92m
Inkomsten(TTM)	-€34.78m
Inkomsten(TTM)	€8.18m

5.6x

P/S-verhouding

-1.3x

Koers/Winstverhouding

Is 135A overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
135A resultatenrekening (TTM)
Inkomsten	US$8.57m
Kosten van inkomsten	US$14.68m
Brutowinst	-US$6.12m
Overige uitgaven	US$30.32m
Inkomsten	-US$36.44m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.96
Brutomarge	-71.42%
Nettowinstmarge	-425.41%
Schuld/Eigen Vermogen Verhouding	22.6%

Hoe presteerde 135A op de lange termijn?

Bekijk historische prestaties en vergelijking

135A Overzicht aandelen

Beloningen

Risicoanalyse

SCYNEXIS, Inc. Concurrenten

DB:93M1

€102.8m

DB:0RX

€65.0m

XTRA:HIGH

€57.9m

DB:2FJ0

€92.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. to Report Q3, 2024 Results on Oct 18, 2024

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$2.56 profit in 2Q 2023)

First quarter 2024 earnings released: EPS: US$0.009 (vs US$0.71 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Recent updates

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. to Report Q3, 2024 Results on Oct 18, 2024

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$2.56 profit in 2Q 2023)

First quarter 2024 earnings released: EPS: US$0.009 (vs US$0.71 loss in 1Q 2023)

New major risk - Revenue and earnings growth

SCYNEXIS, Inc., Annual General Meeting, Jun 19, 2024

SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases

Full year 2023 earnings released: EPS: US$1.40 (vs US$1.47 loss in FY 2022)

Bronstein, Gewirtz & Grossman LLC Announces SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.62 loss in 3Q 2022)

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology

SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance

Investor sentiment improves as stock rises 17%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: US$2.56 (vs US$0.31 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.17 loss in 1Q 2022)

Forecast breakeven date moved forward to 2023

Forecast to breakeven in 2025

Scynexis AnnouncesFDA Approval of Second Indication for Brexafemme® (Ibrexafungerp Tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Insufficient new directors

Third quarter 2022 earnings released: US$0.62 loss per share (vs US$0.023 loss in 3Q 2021)

SCYNEXIS, Inc. Announces Positive Results from Pooled Analysis of Two Phase 3 Studies (VANISH-303 and VANISH-306) in the Journal of Women’s Health

SCYNEXIS, Inc. to Report Q3, 2022 Results on Nov 09, 2022

SCYNEXIS, Inc. Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

SCYNEXIS, Inc. Announces CEO Changes

SCYNEXIS, Inc. Presents Positive Interim Data of ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.064 profit in 2Q 2021)

SCYNEXIS, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting

SCYNEXIS, Inc. Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME

Scynexis Presents Positive Data from Phase 3 Candle Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the Issvd Xxvi World Congress and International Vulvovaginal Disease Update

Scynexis Announces Initiation of New Phase 3B Study (Vanquish) to Evaluate Oral Ibrexafungerp as A Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

SCYNEXIS, Inc. Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

SCYNEXIS, Inc., Annual General Meeting, Jun 16, 2022

SCYNEXIS, Inc. Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

SCYNEXIS, Inc. to Report Q1, 2022 Results on May 12, 2022

No longer forecast to breakeven

Insufficient new directors

SCYNEXIS, Inc. has completed a Follow-on Equity Offering in the amount of $44.988333 million.

SCYNEXIS, Inc. Announces Positive Interim Data from its Ongoing Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

No longer forecast to breakeven

SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections

Insufficient new directors

Forecast to breakeven in 2024

SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis

Scynexis, Inc. Announces Peer-Reviewed Publication of Results

Scynexis, Inc. Announces U.S. Availability of BREXAFEMME®

Scynexis, Inc. Announces Hansoh Pharma’S Application to National Medical Products Administration (Nmpa) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (Vvc)

SCYNEXIS, Inc. Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and in Vitro Activity Against Candida Species At the 31st ECCMID

SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)

SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections

SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections

Forecast breakeven pushed back to 2024

SCYNEXIS, Inc. Provides an Update on Recent Clinical and Corporate Developments

SCYNEXIS, Inc. announced that it expects to receive funding from Hercules Capital, Inc.

Scynexis Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (Furi and Cares)